Research
Hormonal
Gut microbiota dysbiosis in GDM involves elevated lipopolysaccharide (LPS) production and translocation, leading to low-grade inflammation and insulin resistance.
High levels of certain gut bacteria (pathobionts) can lead to inflammation and insulin resistance. While this is a key mechanism in GDM, it is not yet clear if fixing the microbiota alone will cure GDM. Focus on overall metabolic health.
ModerateSupportsMEDIUM confidence
Elevation of LPS is associated with low-grade inflammatory pathways, attenuation of insulin signaling, and glucose intolerance... Possible mechanisms on how gut dysbiosis influences gut epithelial permeability, colonic LPS concentration, low-grade inflammation, and insulin resistance in women with GDM will be discussed...
Why this rating
Based on mouse models and some human studies, but direct causality in GDM is not fully established.
Source
Gut Microbiota and Gestational Diabetes Mellitus: A Review of Host-Gut Microbiota Interactions and Their Therapeutic Potential
Zubaidah Hasain et al. · Frontiers in Cellular and Infection Microbiology · 2020
DOI 10.3389/fcimb.2020.00188
narrative_reviewCited 224×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modification and metformin treatment can modulate gut microbiota and maintain glucose homeostasis in type 2 diabetes, suggesting similar potential for post-GDM women.Good
- Gut microbiota dysbiosis, characterized by elevated pathobionts (e.g., Proteobacteria, Enterobacteriaceae) and depleted beneficial bacteria (e.g., Faecalibacterium, Bifidobacterium), is associated with gestational diabetes mellitus (GDM) and postpartum glucose intolerance, potentially serving as a predictive biomarker for type 2 diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →